KalVista Pharmaceuticals (KALV) Leases (2019 - 2025)
KalVista Pharmaceuticals' Leases history spans 6 years, with the latest figure at $5.5 million for Q2 2025.
- On a quarterly basis, Leases fell 19.88% to $5.5 million in Q2 2025 year-over-year; TTM through Apr 2025 was $5.5 million, a 19.88% decrease, with the full-year FY2025 number at $5.5 million, down 19.88% from a year prior.
- Leases hit $5.5 million in Q2 2025 for KalVista Pharmaceuticals, down from $5.6 million in the prior quarter.
- Over the last five years, Leases for KALV hit a ceiling of $7.8 million in Q2 2023 and a floor of $1.7 million in Q1 2021.
- Historically, Leases has averaged $6.1 million across 4 years, with a median of $5.9 million in 2024.
- Biggest five-year swings in Leases: skyrocketed 257.2% in 2021 and later dropped 22.61% in 2024.
- Tracing KALV's Leases over 4 years: stood at $5.8 million in 2021, then grew by 26.75% to $7.3 million in 2023, then fell by 23.62% to $5.6 million in 2024, then dropped by 0.54% to $5.5 million in 2025.
- Business Quant data shows Leases for KALV at $5.5 million in Q2 2025, $5.6 million in Q4 2024, and $5.9 million in Q4 2024.